Overview

Description

  • Nature
    Recombinant
  • Amino Acid Sequence
    • Species
      Human

Associated products

Specifications

Our Abpromise guarantee covers the use of ab113305 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking - Blocking peptide for Anti-Wnt7a antibody (ab100792)

  • Form
    Liquid
  • Additional notes

    This is the blocking peptide for ab100792.

    - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
    - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
    - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
    - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
    - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    Information available upon request.

General Info

  • Alternative names
    • Protein Wnt-7a
    • Protein Wnt-7a precursor
    • Proto oncogene Wnt7a protein
    • proto-oncogene wnt7a protein
    • wingless-type MMTV integration site family, member 7A
    • Wnt family member 7A
    • WNT7A
    • WNT7A_HUMAN
    see all
  • Function
    Ligand for members of the frizzled family of seven transmembrane receptors. Probable developmental protein. Signaling by Wnt-7a allows sexually dimorphic development of the mullerian ducts.
  • Tissue specificity
    Expression is restricted to placenta, kidney, testis, uterus, fetal lung, and fetal and adult brain.
  • Involvement in disease
    Defects in WNT7A are the cause of limb/pelvis-hypoplasia/aplasia syndrome (LPHAS) [MIM:276820]; also known as absence of ulna and fibula with severe limb deficiency. LPHAS is a limb-malformation disorder characterized by various degrees of limb aplasia/hypoplasia and joint dysplasia.
    Defects in WNT7A are a cause of Fuhrmann syndrome (FUHRS) [MIM:228930]; also known as fibular aplasia or hypoplasia femoral bowing and poly- syn- and oligodactyly. Fuhrmann syndrome is a distinct limb-malformation disorder characterized also by various degrees of limb aplasia/hypoplasia and joint dysplasia.
  • Sequence similarities
    Belongs to the Wnt family.
  • Cellular localization
    Secreted > extracellular space > extracellular matrix.
  • Information by UniProt

References for Human Wnt7a peptide (ab113305)

ab113305 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab113305.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up